Related Experiment Videos

A single center experience of stenting in symptomatic intracranial atherosclerosis

C Castaño1, P García-Bermejo, M R García

  • 1Unit of Interventional Neuroradiology, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Universidad Autónoma de Barcelona; Badalona-Barcelona, Spain - ccastanod@gmail.com.

The Neuroradiology Journal
|September 14, 2013
PubMed

Insights

Intracranial stenting for atherosclerotic stenosis may be safe and effective, even after conflicting trial results. Careful patient selection and technique are key to successful outcomes and preventing stroke recurrence.

Area of Science:

  • Neurology
  • Interventional Cardiology
  • Vascular Surgery

Background:

  • Atherosclerotic intracranial arterial stenosis is a significant cause of stroke.
  • Percutaneous transluminal angioplasty and stenting (PTAS) is used to prevent recurrent stroke.
  • The SAMMPRIS trial indicated aggressive medical management is superior to PTAS with the Wingspan stent system.

Purpose of the Study:

  • To evaluate the safety and efficacy of intracranial stenting for atherosclerotic stenosis.
  • To assess clinical outcomes and complications in patients treated with the Wingspan stent system.

Main Methods:

  • Retrospective, single-center study of seven consecutive patients.
  • Patients had symptomatic, angiographically proven atherosclerotic intracranial arterial stenosis.
  • All patients received adjuvant antiplatelet therapy and underwent stenting with the Wingspan system under general anesthesia.

Main Results:

  • Successful revascularization was achieved in all patients.
  • Four patients had no residual stenosis; three had 20-40% residual stenosis.
  • 100% of patients showed clinical improvement and good functional outcomes at three months (modified Rankin Scale score ≤ 2).
  • No peri-interventional events or neurologic complications occurred.

Conclusions:

  • Intracranial stenting, when performed with meticulous technique and careful patient selection, appears safe and effective.
  • These findings contrast with the SAMMPRIS trial, suggesting a potential role for PTAS in select cases.
  • Further research is warranted to define optimal patient selection criteria for intracranial stenting.